Blog
August 9, 2026
Dry eye is common; autoimmune disease is a much narrower explanation. The challenge is recognizing the patients whose ocular surface is signaling a broader disorder without frightening every person with seasonal burning or screen fatigue.
Sjögren disease is the best-known connection because immune activity targets lacrimal and salivary glands, reducing tears and saliva. Yet the condition is systemic, and its diagnosis cannot be made by Schirmer paper or an online symptom list. Other immune disorders affect the eye through gland inflammation, eyelid and connective-tissue change, medication exposure, nerve dysfunction or scarring.
This article focuses on those systemic connections. It complements Netra Eye Institute’s dry-eye condition page and does not replace rheumatologic or ophthalmic diagnosis.
Sjögren disease is a chronic autoimmune disorder in which immune cells and signaling disrupt exocrine glands, especially lacrimal and salivary tissue. It can occur alone or alongside another autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus.
The older term “primary” distinguishes disease occurring without another systemic autoimmune diagnosis, while “secondary” has been used when another disease is present. Current language increasingly treats Sjögren disease as its own spectrum and avoids implying that gland symptoms are secondary or unimportant.
Reduced tears and saliva are prominent, but systemic manifestations may affect peripheral or central nerves, lungs, kidneys, blood vessels, skin, joints and blood cells. Patients also have an increased risk of lymphoma compared with the general population, although the absolute risk for an individual remains limited and depends on clinical factors.
This systemic scope is why dry-eye drops alone are not a complete Sjögren plan.
Immune-mediated lacrimal dysfunction reduces aqueous secretion. The remaining tear volume evaporates and becomes hyperosmolar more quickly. Hyperosmolarity stresses epithelial cells, activates inflammatory pathways and damages the mucin–glycocalyx interface.
Conjunctival goblet-cell dysfunction and epithelial change impair wettability. Meibomian-gland dysfunction may coexist, creating mixed evaporative and aqueous-deficient disease. Corneal nerves can be irritated, damaged or sensitized, so pain does not always track staining.
The result may include:
Severe disease can threaten the cornea through ulceration, infection, thinning or perforation. These outcomes are uncommon but explain why objective protection matters even when symptoms fluctuate.
Dry mouth may present as constant sipping, difficulty swallowing dry food, waking for water, altered taste, hoarseness or trouble speaking for long periods. Dental caries, oral candidiasis and salivary-gland swelling are important clues.
Systemic symptoms can include fatigue, joint or muscle pain, Raynaud phenomenon, rash, numbness or burning neuropathy, cough, shortness of breath and kidney or urinary abnormalities. Many of these are nonspecific; their presence does not prove Sjögren disease.
Medication can mimic sicca. Antihistamines, anticholinergic drugs, antidepressants, diuretics and other medicines can reduce tears or saliva. Diabetes, thyroid disease, hepatitis C, HIV, sarcoidosis, prior radiation and aging belong in the differential.
The pattern and objective findings determine whether systemic evaluation is warranted.
Suspicion rises with marked aqueous deficiency, severe conjunctival staining, symptoms requiring frequent preservative-free drops, dry mouth, salivary swelling, early dental disease, systemic features or a family or personal autoimmune history.
Age and sex influence probability but do not exclude anyone. Sjögren disease is more common in women and often recognized in midlife, yet men and younger patients can be affected. Long diagnostic delays occur because symptoms are distributed across dentistry, primary care, rheumatology and eye care.
An eye clinician may document OSDI or another symptom measure, Schirmer results and ocular-surface staining. These findings contribute to classification but are not sufficient alone.
Anti-SSA/Ro is an important autoantibody in Sjögren evaluation. Anti-SSB/La, ANA and rheumatoid factor can add context. Complete blood count, metabolic testing, inflammatory markers, immunoglobulins, complement and urine studies may be ordered according to systemic concerns.
Several cautions matter:
Commercial “early Sjögren” antibody panels include markers with less-established diagnostic roles. They should not substitute for rheumatologic assessment or be marketed as definitive.
Unstimulated whole salivary flow measures objective oral dryness. Salivary-gland ultrasound is used increasingly in some centers. Minor salivary-gland biopsy from the lip can identify focal lymphocytic sialadenitis and contribute strongly to classification.
Biopsy is not required for every dry-eye patient. It has procedural risks and requires experienced pathology. It may be valuable when clinical suspicion remains high despite negative serology or when diagnostic certainty will change systemic management.
Dentists and oral-medicine specialists can document caries, candidiasis, mucosal injury and salivary dysfunction while providing preventive care.
The 2016 ACR/EULAR classification criteria assign weighted points for anti-SSA positivity, a positive minor salivary-gland biopsy, ocular staining, low Schirmer wetting and reduced salivary flow. A threshold classifies patients after inclusion and exclusion conditions are considered.
These criteria were designed for uniform research classification. A rheumatologist evaluates the whole patient, exclusions and organ involvement. An ocular score cannot be interpreted correctly without the specified staining method and trained examiner.
Patients often move between optometry, ophthalmology, dentistry, primary care and rheumatology before the pattern is recognized. Each discipline sees a different part: low tears, recurrent caries, fatigue, neuropathy or positive antibodies. A concise shared history can shorten that delay.
The diagnostic process usually has several layers:
Some patients have incomplete or evolving disease. Clinicians may monitor rather than force an immediate label. That uncertainty should not prevent treatment of a damaged ocular surface.
At the other extreme, a low-positive ANA discovered in a patient with ordinary MGD can trigger unnecessary fear. The predictive value of a result depends on the pretest clinical picture. A rheumatologist can interpret titer, pattern and accompanying findings rather than treating every positive result as systemic disease.
Peripheral neuropathy may cause numbness, burning, imbalance or autonomic symptoms. Small-fiber neuropathy can be painful despite normal routine nerve-conduction studies. Cranial nerve and central nervous system manifestations are less common but important.
Corneal nerve symptoms can coexist with systemic neuropathy. Severe ocular burning with limited staining should not be dismissed, yet it also should not automatically be attributed to Sjögren inflammation. Corneal and neurologic assessment can identify overlapping surface and neuropathic pain.
Persistent cough or shortness of breath may reflect airway dryness, interstitial lung disease or another cardiopulmonary problem. These symptoms require medical assessment; humidification and eye treatment are not sufficient. Baseline and follow-up testing depend on clinical risk.
Tubulointerstitial nephritis and renal tubular acidosis can occur. Vasculitis may affect skin, nerves and organs. Urine, electrolytes, kidney function, complement and other studies may be used when features suggest involvement.
Sjögren disease is associated with an increased lymphoma risk. Persistent salivary-gland enlargement, lymph nodes, unexplained weight loss, fevers, night sweats, low complement, cryoglobulins or specific blood abnormalities require prompt medical attention. Most patients do not develop lymphoma, so the message is informed surveillance rather than alarm.
No single systemic medicine treats every Sjögren manifestation. Hydroxychloroquine may be used for selected musculoskeletal or systemic features, while corticosteroids, conventional immunosuppressants or biologic agents are reserved for particular organ disease and activity. Evidence for improving dryness alone is limited.
Rituximab and other biologics have been studied with mixed results depending on outcome and subgroup. New agents continue to be investigated. Treatment decisions balance organ threat, symptoms, infection risk and comorbidity; they should not be driven by ocular dryness alone.
Hydroxychloroquine requires retinal toxicity screening based on dose, duration and risk factors. This is separate from dry-eye monitoring. Patients should not stop an effective systemic medicine because they confuse retinal screening with surface discomfort.
Systemic corticosteroids can temporarily alter inflammation but carry metabolic, bone, infection, cataract and glaucoma risks. Topical eye steroids have their own pressure and infection risks. Coordination avoids duplicated exposure and ensures the right clinician monitors each risk.
Saliva buffers acid, controls microbes, supports swallowing and protects teeth. Low flow increases caries, erosion, candidiasis and oral discomfort. Prevention may include frequent dental visits, prescription-strength fluoride, saliva substitutes or stimulants, and careful dietary choices.
Sipping sugary or acidic beverages for relief can accelerate decay. Sugar-free gum or lozenges may stimulate residual saliva when safe, but jaw disease, aspiration risk and gastrointestinal tolerance matter. Cevimeline or pilocarpine may help selected patients but can cause sweating, flushing, urinary frequency and cardiopulmonary effects.
Oral candidiasis may cause burning, altered taste or white/red lesions and needs diagnosis. Recurrent salivary swelling or infection deserves evaluation rather than repeated self-massage.
Eye clinicians asking about oral health is not scope creep; it identifies a systemic pattern and prevents missed referrals.
Sjögren disease predominantly affects women, but men can have significant systemic disease and may be underrecognized. Symptoms can appear before, during or after menopause. Hormonal context may influence the ocular surface, but hormone replacement is not a direct Sjögren treatment.
Pregnancy planning deserves specialist coordination. Anti-SSA/Ro and anti-SSB/La antibodies can be associated with neonatal lupus and congenital heart block in a small proportion of pregnancies, so obstetric and rheumatologic monitoring matters. Patients should not discontinue necessary medicine abruptly when planning conception.
Topical and systemic dry-eye treatments, herbs and supplements require pregnancy and breastfeeding review. Some oral antibiotics and retinoids are contraindicated. Punctal occlusion during eye-drop instillation can reduce systemic absorption but does not eliminate the need for medication guidance.
Immunosuppressive therapy can increase infection risk, while a damaged dry ocular surface weakens a protective barrier. Redness, discharge, focal opacity or sudden pain should be examined. Reusing contaminated bottles, extending single-use vials or placing homemade remedies in the eye is particularly risky.
Scleral and bandage lenses require meticulous hygiene. Fever or systemic infection may affect whether immunosuppressive doses continue; that decision belongs to the treating medical team.
Vaccination planning, screening for latent infection before biologic therapy and monitoring blood counts or liver function are systemic responsibilities. Integrative clinicians should be aware of them to avoid interactions, but must not independently alter the regimen.
Chronic dryness, fatigue and pain can reduce work, reading, driving, sleep and social participation. The invisibility of symptoms may lead to disbelief. Depression and anxiety can coexist, influence pain processing and deserve treatment without implying that symptoms are imaginary.
Practical accommodations can include flexible breaks, humidity or airflow changes, larger text, voice input, moisture-chamber eyewear and scheduling demanding tasks during better hours. Occupational therapy and low-vision services can help when visual function remains limited.
Peer support may reduce isolation, but online communities also spread high-dose supplement and restrictive-diet claims. A patient should not be blamed for disease because a diet did not “heal autoimmunity.” Nutritional support should preserve adequacy and quality of life.
A patient has very low Schirmer wetting, significant ocular staining, dry mouth and dental disease but negative SSA. The appropriate response is not “no Sjögren.” Rheumatology reviews other causes, examination and potential salivary testing or biopsy while eye treatment protects the cornea.
A patient with screen-related late-day burning has good tear volume, obstructive glands and no oral or systemic symptoms. A low-positive ANA found elsewhere does not override the phenotype. Gland and exposure care proceed, and systemic referral depends on the broader history.
A patient with RA reports unilateral deep tenderness and redness. Scleritis must be excluded urgently. Treating the eye as a dry-eye flare with retail drops could delay systemic immunosuppression needed to prevent damage.
A patient after allogeneic stem-cell transplantation develops severe dryness and photophobia. Ocular graft-versus-host disease requires prompt corneal and transplant-team coordination. Early aggressive protection may prevent scarring and loss.
Researchers are studying tear and blood biomarkers, salivary ultrasound, interferon pathways, B-cell therapies, microbiome associations and regenerative approaches. These areas may improve classification and targeted treatment, but many are not ready for routine claims.
Association between gut microbiota and autoimmune dry eye does not prove that commercial probiotics or restrictive diets alter organ disease. A laboratory reduction in cytokines does not establish clinical benefit. NRT discussions should distinguish biologic rationale from patient-level outcomes.
Clinical trials benefit from standardized criteria, while real patients often have mixed disease and comorbidities. That is why shared decision-making and careful follow-up remain important even as evidence evolves.
Follow-up intervals depend on corneal severity, treatment changes and organ risk. Ocular visits may repeat staining, tear volume, lens fit, pressure when steroids are used and the patient’s ability to perform key tasks. A symptom improvement is welcome but does not prove that epithelial risk has resolved.
Rheumatology follow-up may review new organ symptoms, examination, laboratory trends and medication toxicity. Dentistry monitors caries and oral infection. Pulmonary, neurologic, renal, hematologic or maternal-fetal specialists become involved when the disease pattern requires them.
Patients benefit from one updated medication list and a clear emergency plan. New focal neurologic symptoms, shortness of breath, persistent gland enlargement, constitutional symptoms or sudden eye change should be communicated promptly. Coordinated monitoring is more effective than expecting one specialty to interpret every manifestation.
Rheumatoid arthritis can coexist with Sjögren disease or produce ocular-surface inflammation independently. Dry eye is common, but more urgent complications include episcleritis, scleritis and peripheral ulcerative keratitis.
Scleritis produces deep pain and tenderness and can threaten vision. Peripheral ulcerative keratitis causes corneal thinning near the limbus and may signal active systemic vasculitis. These are not treated as routine dryness and require urgent ophthalmology and rheumatology coordination.
Systemic immunomodulatory treatment may be essential. Artificial tears cannot control destructive vasculitic disease.
Lupus can be associated with dry eye through secondary Sjögren disease, inflammation, medication and eyelid or retinal manifestations. Retinal vascular disease and optic-nerve involvement cause vision changes that lubrication cannot address.
Hydroxychloroquine is commonly used for lupus and other rheumatic disease. It can rarely cause retinal toxicity with cumulative exposure, so risk-based screening is important. Patients should not stop it because of dry-eye symptoms; systemic benefit and retinal monitoring are separate issues.
Systemic sclerosis can alter eyelids, conjunctiva, meibomian glands and tear secretion. Tight skin and incomplete closure may add exposure. Patients may also have reflux, lung or vascular disease that changes treatment choices.
The eye plan targets the actual phenotype, while systemic clinicians manage the underlying connective-tissue disease.
Autoimmune thyroid disease can coexist with dry eye, but thyroid eye disease adds a mechanical mechanism. Lid retraction, proptosis and incomplete closure expose the cornea. Inflammation within the orbit may cause pain, double vision, color change or optic-nerve compression.
Normal thyroid hormone levels do not guarantee that orbital disease is inactive. New reduced vision, color desaturation, severe exposure or double vision requires specialist assessment. Lubrication is supportive; active or sight-threatening thyroid eye disease needs disease-specific care.
Crohn disease and ulcerative colitis can be associated with dry eye, episcleritis or uveitis. Uveitis typically causes pain, light sensitivity and blur and requires examination. Some systemic biologic medicines improve inflammation, while others can create ocular adverse effects.
Psoriasis and psoriatic arthritis may be associated with MGD and ocular inflammation. Atopic disease can affect lids and conjunctiva. The presence of a systemic label does not determine the ocular mechanism automatically.
Sarcoidosis can involve lacrimal glands, conjunctiva, uvea, optic nerve and orbit. Lacrimal enlargement or reduced secretion may resemble Sjögren disease. Uveitis and neurologic involvement require targeted systemic workup.
A dry-eye diagnosis should not close the differential when there is granulomatous inflammation, gland enlargement or other organ involvement.
After allogeneic hematopoietic stem-cell transplantation, donor immune cells can attack recipient tissues, including lacrimal glands, conjunctiva and meibomian glands. Ocular graft-versus-host disease can be severe and rapidly impair quality of life.
Treatment may involve preservative-free lubrication, anti-inflammatory drops, serum tears, punctal occlusion, scleral lenses, systemic therapy and advanced surface protection. Infection risk and immunosuppression require coordinated transplant and corneal care.
This is not an ordinary retail dry-eye problem.
Mucous membrane pemphigoid and Stevens-Johnson syndrome can scar conjunctiva, shorten fornices, turn lashes inward and damage goblet cells, glands and cornea. Progression may be subtle while scarring advances.
Systemic immunosuppression is often needed to stop cicatrization. Lid surgery or surface reconstruction may be considered only within disease control. NRT or supplements cannot replace immunologic treatment.
There is no single symptom that proves autoimmunity. Clues become persuasive in combination: severe objective aqueous deficiency, oral sicca, dental disease, salivary swelling, systemic symptoms, autoimmune history and characteristic laboratory or biopsy findings.
Common MGD can occur in a patient with rheumatoid arthritis; a healthy screen user can have dry mouth from antihistamines. Conversely, a patient with Sjögren disease may also have significant MGD and exposure. Diagnosis prevents both under-referral and over-labeling.
Preservative-free tears, gels and ointments reduce friction and add moisture. Moisture-chamber eyewear and environmental control reduce evaporation. Frequent preserved drops can add toxicity.
Topical cyclosporine, lifitegrast and short monitored steroid courses may be used. Response varies, and severe gland destruction may limit tear-production gains. Steroid risks include pressure elevation, cataract and infection.
Punctal plugs or cautery retain tears in selected patients. Oral secretagogues can improve oral and sometimes ocular secretion but have systemic adverse effects. Varenicline nasal spray stimulates natural tearing in appropriate adults.
Autologous serum or platelet-derived drops supply epitheliotrophic factors. Scleral lenses maintain a fluid reservoir and protect severe surfaces. Handling, fogging, hypoxia and infection require expert monitoring.
Filament removal, amniotic membrane, tarsorrhaphy, nerve-growth-factor therapy and surgery may be needed for persistent defects or neurotrophic disease. Corneal thinning or ulceration is urgent.
Rheumatologic therapy targets systemic immune disease and organ risk. Improvement in joints or laboratory markers does not guarantee restored tear secretion. Some systemic medicines have ocular or infection risks.
Eye and systemic clinicians should share medication, activity and monitoring information. The patient should know which clinician manages each problem.
People with dry mouth need regular dental care, fluoride strategies, saliva support and candidiasis awareness. Frequent sugary lozenges can worsen caries. Hydration helps comfort but cannot reverse gland damage.
For the eyes, avoid direct airflow, smoke, nonsterile products and unnecessary preserved drops. Use screen breaks and complete blinks. Follow contact-lens and scleral-lens hygiene precisely.
Vaccination, infection prevention and bone or cardiovascular care may be relevant depending on systemic treatment. These belong with the responsible medical team.
Netra Restoration Therapy (NRT) may provide complementary support for symptom burden, stress, sleep, nutrition and selected inflammatory or autonomic contributors while ophthalmic and rheumatologic treatment continues.
Acupuncture studies in dry eye report improvements in selected tear and symptom outcomes. A small 2025 sham-controlled Sjögren trial evaluated ocular and oral symptoms, but enrollment and completion were limited. These data are preliminary and do not establish modification of systemic autoimmunity or reversal of lacrimal-gland destruction.
An evidence-bounded NRT plan sets modest goals such as reduced discomfort or improved daily function, monitors ocular safety and communicates with rheumatology. It does not advise stopping hydroxychloroquine, biologics, steroids, prescription drops or systemic secretagogues.
Oral herbs can interact with anticoagulants, immunosuppressants, liver metabolism and surgery. Immunocompromised patients face additional contamination risk. No nonsterile herbal preparation should enter the eye.
Learn about Netra Restoration Therapy for dry eye, Netra Eye Institute’s approach, dry-eye testing and how to request an appointment.
No. Severe disease has many causes. Sjögren evaluation is guided by ocular findings, oral symptoms, systemic history and appropriate tests.
Yes. Some patients are seronegative, so rheumatologists may consider salivary testing or biopsy when suspicion remains high. Negative tests still lower probability in context.
Systemic treatment protects organs and controls disease but does not reliably restore established lacrimal function. Local ocular protection often remains necessary.
Not always. RA can coexist with Sjögren or cause other ocular inflammation. Scleritis and peripheral corneal disease are urgent distinct complications.
No reliable clinical evidence supports using NRT to normalize antibodies or replace systemic treatment. It may be considered only as adjunctive supportive care.
Autoimmune dry eye sits at the intersection of ocular-surface protection and systemic medicine. The eye may reveal a broader disease, but common dryness should not be overdiagnosed as autoimmunity. Careful phenotype, oral and systemic history, appropriate testing and coordinated treatment provide the safest path.
NRT may complement symptom and whole-person support when it respects that boundary. Corneal safety and systemic disease control remain the responsibilities of qualified ophthalmic and medical teams.
Patients should keep one concise summary of diagnoses, antibodies, biopsy findings, organ involvement, current immune therapy and ocular-surface treatment. That document reduces fragmented care and helps clinicians distinguish a new manifestation from medication toxicity or common unrelated disease. Coordination is especially important before surgery, pregnancy, vaccination changes or treatment with a new biologic agent.
It should include allergies, prior infections and emergency contacts so urgent decisions reflect the complete immune and ocular risk profile.
Medical Disclaimer: This article is general education and is not medical advice, autoimmune diagnosis or treatment. Dry eye can reflect common local disease or serious systemic and corneal conditions. Seek urgent eye care for sudden vision loss, severe pain, marked light sensitivity, focal opacity, trauma, discharge or an epithelial defect. Do not stop rheumatologic, thyroid, psychiatric, cardiovascular, oncology or eye medicines without the responsible clinician. Netra Restoration Therapy is adjunctive and cannot replace ophthalmology, rheumatology, biopsy, systemic immunotherapy or emergency care.
